STOCK TITAN

Edwards Lifesciences (EW) CVP awarded stock, options and performance rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP TAVR, reported equity compensation awards and related tax withholding transactions in company stock. He received 7,850 shares of common stock as a grant and 7,850 performance rights tied to common stock, all under the company’s Long-Term Stock Incentive Compensation Program. He was also granted 39,900 employee stock options exercisable at $82.76 per share, scheduled to vest in four equal annual installments beginning one year after the grant date. To cover tax obligations on awards vesting, 450 shares and 309 shares of common stock were withheld at prices of $82.76 and $83.20 per share, respectively. After these transactions, Lippis directly holds 40,772.9103 shares of Edwards Lifesciences common stock.

Positive

  • None.

Negative

  • None.
Insider Lippis Daniel J.
Role CVP, TAVR
Type Security Shares Price Value
Tax Withholding Common Stock 450 $82.76 $37K
Grant/Award Employee Stock Option (Right to Acquire) 39,900 $0.00 --
Grant/Award Performance Rights 7,850 $0.00 --
Grant/Award Common Stock 7,850 $0.00 --
Tax Withholding Common Stock 309 $83.20 $26K
Holdings After Transaction: Common Stock — 40,772.91 shares (Direct, null); Employee Stock Option (Right to Acquire) — 39,900 shares (Direct, null); Performance Rights — 7,850 shares (Direct, null)
Footnotes (1)
  1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
Common stock grant 7,850 shares Equity award of common stock granted May 7, 2026
Performance rights target 7,850 units Target performance rights linked to common stock vesting May 7, 2029
Stock options granted 39,900 options Employee stock options granted May 7, 2026
Option exercise price $82.76 per share Conversion or exercise price for 39,900 options
Tax-withheld shares 759 shares Shares withheld to cover tax liabilities on May 7–8, 2026
Holding after transactions 40,772.9103 shares Common stock directly held after reported Form 4 transactions
Tax withholding price 1 $82.76 per share Price used for 450 tax-withheld shares on May 8, 2026
Tax withholding price 2 $83.20 per share Price used for 309 tax-withheld shares on May 7, 2026
restricted stock units financial
"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance rights financial
"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 ... scheduled to vest on May 7, 2029."
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
Long-Term Stock Incentive Compensation Program financial
"granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
employee stock option financial
"Employee Stock Option (Right to Acquire) ... are scheduled to become vested and exercisable commencing one year after the grant date"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
performance goals financial
"The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period"
Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lippis Daniel J.

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CVP, TAVR
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A7,850(1)A$0.000041,531.9103D
Common Stock05/07/2026F309D$83.241,222.9103D
Common Stock05/08/2026F450D$82.7640,772.9103D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Acquire)$82.7605/07/2026A39,90005/07/2027(2)05/06/2033Common Stock39,900$0.000039,900D
Performance Rights(3)05/07/2026A7,85005/07/2029 (3)Common Stock7,850$0.00007,850D
Explanation of Responses:
1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
2. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
3. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Daniel J. Lippis report in his latest Form 4 for Edwards Lifesciences (EW)?

Daniel J. Lippis reported new equity compensation awards and tax-related share withholdings. He received 7,850 shares of common stock, 7,850 performance rights, and 39,900 stock options, while 759 shares were withheld to satisfy tax obligations tied to vesting awards.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after these transactions?

Following the reported transactions, Daniel J. Lippis directly holds 40,772.9103 shares of Edwards Lifesciences common stock. This figure reflects his position after both the equity grants and the tax-withholding share dispositions recorded in the Form 4 filing.

What equity awards did Daniel J. Lippis receive from Edwards Lifesciences (EW)?

He received 7,850 shares of common stock, 7,850 performance rights, and 39,900 employee stock options. The options have an exercise price of $82.76 per share and, along with certain restricted units, vest in four equal annual installments starting one year after the grant.

What are the terms of Daniel J. Lippis’s new stock options at Edwards Lifesciences (EW)?

Lippis was granted 39,900 employee stock options with a conversion or exercise price of $82.76 per share. These options were granted on May 7, 2026 and are scheduled to vest and become exercisable in four equal annual installments beginning one year after the grant date.

Why were some Edwards Lifesciences (EW) shares disposed of in Daniel J. Lippis’s Form 4?

The reported share dispositions reflect tax-withholding transactions, not open-market sales. A total of 759 shares of common stock were withheld at prices of $82.76 and $83.20 per share to satisfy tax liabilities associated with his equity compensation awards.

How do the performance rights granted to Daniel J. Lippis at Edwards Lifesciences (EW) work?

Lippis received 7,850 performance rights linked to an equal number of common shares. These rights are scheduled to vest on May 7, 2029, with the actual number vesting ranging from 0% to 200% of the target amount based on achievement of specified three-year performance goals.